PUBLIC COMPANY
saveCYTOKINETICS
USupdated 5mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- phase3A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
- phase3Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
🐶 Hiring Signal
News
- WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlightThe year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.biopharma_dive · 15d ago
- ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsyAt a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.biopharma_dive · 1mo ago
- A winner, a loser, and a mid-stage signal from a major cardiology research conferenceThe mental health system after Lindsay Clancy, pushing boundaries for new radiopharmaceuticals, and more health news from Morning Roundsstat · 1mo ago
- STAT+: After a rough stretch, mRNA gets a boost — at least for nowWith clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the technology in other areas.stat · 1mo ago
- STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapyResearchers believe radiopharmaceuticals have great promise as cancer treatments. But are they using them too timidly?stat · 1mo ago
- STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancerMimrylo, from Takeda and Protagonist, is a new kind of treatment for the blood cancer polycythemia vera.stat · 1mo ago
- STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s WainuaAn AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.stat · 1mo ago
- STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watchingRoivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech newsstat · 1mo ago
- STAT+: Cytokinetics details trial win for what could be its next approvalIt took Cytokinetics 27 years to win its first drug approval. With the results of a new trial, its second could come much faster.stat · 1mo ago
- #ESC26: Data in hand, Cytokinetics looks to expanded Myqorzo approvalMUNICH — Cytokinetics’ heart drug Myqorzo could gain expanded approval next year, potentially doubling its market reach, after detailed results backed the drug’s use in a heart muscle disease. The…endpoints · 1mo ago
comments(0)
5-min edit window · permanent after that